Utilization of antidiabetic medicines in Republic of Kosova
Session
Pharmaceutical and Natural Sciences
Description
Diabetes is a common disease among the Kosovo population, and in cases where chronic patients experience comorbidities, it can be severe and fatal. In the last three years, some new medicines have been registered in Kosovo Medicines Agency for the treatment of diabetes (oral medicines and new analog insulins) that aim the better outcomes for the treatment of the patients.
This study aims to analyze the drug utilization of antidiabetic medicines in Kosovo and compare the pre-pandemics utilization and with that in other countries. Another objective is to compare the essential medicines list revision of 2019 and the consumption trend due to the changes on the new list.
The methodology of drug consumption is based on the WHO ATC/DDD system, with results shown in DDD/inhabitant/day (DID).
Preliminary results show that Kosovo is also moving with new medicines, but with much slower budget possibilities and a lack of health insurance. The introduction of analog insulins in the essential medicines list and obtaining marketing authorization for some other new oral antidiabetics have open possibilities for patients to access these medicines. However, data show a need for the intervention of clinical pharmacists in the medication review for more rational use of antidiabetic medicines.
Keywords:
Antidiabetic medicines, Essential Medicines, DDD, DID; Drug Consumption
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-550-50-5
Location
UBT Kampus, Lipjan
Start Date
29-10-2022 12:00 AM
End Date
30-10-2022 12:00 AM
DOI
10.33107/ubt-ic.2022.89
Recommended Citation
Jakupi, Arianit; Dragusha, Shpend; Ejupi, Valon; Hoti, Agon; Bajraktari, Demush; Qazimi, Bujar; and Mehmeti, Eda, "Utilization of antidiabetic medicines in Republic of Kosova" (2022). UBT International Conference. 89.
https://knowledgecenter.ubt-uni.net/conference/2022/all-events/89
Utilization of antidiabetic medicines in Republic of Kosova
UBT Kampus, Lipjan
Diabetes is a common disease among the Kosovo population, and in cases where chronic patients experience comorbidities, it can be severe and fatal. In the last three years, some new medicines have been registered in Kosovo Medicines Agency for the treatment of diabetes (oral medicines and new analog insulins) that aim the better outcomes for the treatment of the patients.
This study aims to analyze the drug utilization of antidiabetic medicines in Kosovo and compare the pre-pandemics utilization and with that in other countries. Another objective is to compare the essential medicines list revision of 2019 and the consumption trend due to the changes on the new list.
The methodology of drug consumption is based on the WHO ATC/DDD system, with results shown in DDD/inhabitant/day (DID).
Preliminary results show that Kosovo is also moving with new medicines, but with much slower budget possibilities and a lack of health insurance. The introduction of analog insulins in the essential medicines list and obtaining marketing authorization for some other new oral antidiabetics have open possibilities for patients to access these medicines. However, data show a need for the intervention of clinical pharmacists in the medication review for more rational use of antidiabetic medicines.